trial

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

NCTId NCT00366704
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 400 (estimated)
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Primary completion 2008-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
400 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-11
Primary completion
2008-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
BifeprunoxRisperidone

Sponsors

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor
Solvay PharmaceuticalsCollaborator

Sites

0 total

Linked catalysts

1
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schiz — primary completion2008-03

Facts & assertions

4 sourced
Enrollment
400
Phase
PHASE3
Primary Completion Date
2008-03
Status
TERMINATED
relationships
The graph out of here
drug
Bifeprunox
drug
Risperidone
drug
lead_sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
company
collaborator
Solvay Pharmaceuticals
company
indication
Schizophrenia
indication
Schizophrenia
indication